Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1276247.RAO6SeDawStSTyrxfczV_dZK02sXNSn8Wh02S2Q_zCIBs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1276247.RAO6SeDawStSTyrxfczV_dZK02sXNSn8Wh02S2Q_zCIBs130_assertion type Assertion NP1276247.RAO6SeDawStSTyrxfczV_dZK02sXNSn8Wh02S2Q_zCIBs130_head.
- NP1276247.RAO6SeDawStSTyrxfczV_dZK02sXNSn8Wh02S2Q_zCIBs130_assertion description "[We conducted an open-label trial to assess the efficacy and safety of sofosbuvir (SOF) plus pegylated interferon (Peg-IFN) and ribavirin (RBV) in patients with genotype 1 hepatitis C virus (HCV) who participated in previous studies of one or more Gilead investigational DAAs in combination with RBV with or without Peg-IFN.We enrolled 80 patients at 40 sites.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1276247.RAO6SeDawStSTyrxfczV_dZK02sXNSn8Wh02S2Q_zCIBs130_provenance.
- NP1276247.RAO6SeDawStSTyrxfczV_dZK02sXNSn8Wh02S2Q_zCIBs130_assertion evidence source_evidence_literature NP1276247.RAO6SeDawStSTyrxfczV_dZK02sXNSn8Wh02S2Q_zCIBs130_provenance.
- NP1276247.RAO6SeDawStSTyrxfczV_dZK02sXNSn8Wh02S2Q_zCIBs130_assertion SIO_000772 25847509 NP1276247.RAO6SeDawStSTyrxfczV_dZK02sXNSn8Wh02S2Q_zCIBs130_provenance.
- NP1276247.RAO6SeDawStSTyrxfczV_dZK02sXNSn8Wh02S2Q_zCIBs130_assertion wasDerivedFrom befree-2016 NP1276247.RAO6SeDawStSTyrxfczV_dZK02sXNSn8Wh02S2Q_zCIBs130_provenance.
- NP1276247.RAO6SeDawStSTyrxfczV_dZK02sXNSn8Wh02S2Q_zCIBs130_assertion wasGeneratedBy ECO_0000203 NP1276247.RAO6SeDawStSTyrxfczV_dZK02sXNSn8Wh02S2Q_zCIBs130_provenance.